Mastologia

Riscos de outros tipos de câncer, além dos cânceres de mama e de ovário, associados às variantes patogênicas BRCA1 e BRCA2.

3 Mar, 2022 | 15:45h

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology

Comentário: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge

---

Estudo randomizado | Indicação de exercício precoce e com supervisão após cirurgia de câncer de mama melhora a função do ombro e a qualidade de vida relacionada a saúde.

1 Mar, 2022 | 15:30h

Resumo: Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT – Health Technology Assessment

Relatório completo: Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT – Health Technology Assessment

Conteúdo relacionado: RCT: Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema.

---

Revisão narrativa do painel de especialistas AJR | Algoritmos de rastreamento em mamas densas.

24 Fev, 2022 | 15:35h

Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review – American Journal of Roentgenology

---

Diretriz | Recomendações sobre ultrassonografia mamária – Parte I: técnica de exame, critérios ultrassonográficos e documentação.

17 Fev, 2022 | 14:15h

Best Practice Guideline – DEGUM Recommendations on Breast Ultrasound – Part I – Examination technique, DEGUM ultrasound criteria, and documentation – Ultraschall in der Medizin

---

M-A | Inibidores de aromatase vs. tamoxifeno em mulheres na pré-menopausa com câncer de mama inicial positivo para receptor de estrogênio tratadas com supressão ovariana.

14 Fev, 2022 | 15:34h

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials – The Lancet Oncology

Comentários:

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay

Aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal as well as postmenopausal women – Cancer Research UK

---

Estudo randomizado| Uso profilático de luvas compressoras reduz a incidência de edema de braço em mulheres sob alto risco de linfedema relacionado a câncer de mama.

4 Fev, 2022 | 17:14h

Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema: A Randomized Controlled Trial – Journal of Clinical Oncology

---

Impacto do câncer residual após quimioterapia neoadjuvante e desfechos de sobrevida de longo prazo no câncer de mama: análise multicêntrica de 5.161 pacientes.

4 Fev, 2022 | 15:42h

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients – The Lancet Oncology

Comentário: Long-Term Outcomes According to Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer – The ASCO Post

---

Estudo observacional | Mastectomia e dissecção de linfonodos axilares feitas sem internação e com alta no dia seguinte parecem seguras para a maioria dos pacientes com câncer de mama.

4 Fev, 2022 | 14:53h

Same-day mastectomy and axillary lymph node dissection is safe for most patients with breast cancer – Journal of Surgical Oncology

---

Estudo MINDACT | Desfecho de pacientes com câncer de mama com risco ultrabaixo em painel genético.

25 Jan, 2022 | 11:36h

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer – New England Journal of Medicine

 

Comentário no Twitter:

In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding

8-year DMFI 97%
8-year BCSS 99.6%

Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE

— Paolo Tarantino (@PTarantinoMD) January 22, 2022

 

---

Uso de bisfosfonatos adjuvantes e outros agentes modificadores ósseos no câncer de mama: atualização da diretriz ASCO-OH (CCO).

20 Jan, 2022 | 22:52h

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update – Journal of Clinical Oncology

 

Comentário no Twitter

Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC

Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB

— Paolo Tarantino (@PTarantinoMD) January 18, 2022

 

---